Airway epithelial cell inflammatory signalling in cystic fibrosis

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 9, 2008, Pages 1703-1715

  Jacquot, Jacky ^a,b   Tabary, Olivier ^a,b   Le Rouzic, Philippe ^a,b   Clement, Annick ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Airway epithelial cells; Cystic fibrosis; Glucocorticoids; Inflammation; NF B; Oxidative stress; Signalling

Indexed keywords

ANTIINFLAMMATORY AGENT; CHLORIDE CHANNEL; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; REACTIVE OXYGEN METABOLITE;

BACTERIAL INFECTION; CALCIUM MOBILIZATION; CATARACT; CYSTIC FIBROSIS; GLUCOSE INTOLERANCE; GROWTH DISORDER; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; RESPIRATORY EPITHELIUM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; EPITHELIAL CELLS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS);

EID: 46949105608     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.02.002     Document Type: Review

References (143)

1. Adib-Conquy M., Pedron T., Petit-Bertron A.F., Tabary O., Corvol H., Jacquot J., et al. Neutrophils in cystic fibrosis display a distinct gene expression pattern. Mol. Med. 14 (2008) 36-44
2. Adler K.B., Shapiro S.D., Gallup M., Wu R., Randell S.H., Holtzman M.J., et al. Airway epithelium, inflammation, and mechanisms of disease: A tribute to Carol B. Basbaum. Am. J. Respir. Cell Mol. Biol. 34 (2006) 523-526
3. Amaral M.D., and Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol. Sci. 28 (2007) 334-341
4. Antigny F., Norez C., Becq F., and Vandebrouck C. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 43 (2008) 175-183
5. Auerbach H.S., Williams M., Kirkpatrick J.A., and Colten H.R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2 (1985) 686-688
6. Balfour-Lynn I., Klein N., and Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis 77 (1997) 124-130
7. Balfour-Lynn I.M., Lees B., Hall P., Phillips G., Khan M., Flather M., et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am. J. Respir. Crit. Care Med. 173 (2006) 1356-1362
8. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., and Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr. Pulmonol. 20 (1995) 63-70
9. Barazzone-Argiroffo C., Pagano A., Juge C., Metrailler I., Rochat A., Vesin C., et al. Glucocorticoids aggravate hyperoxia-induced lung injury through decreased nuclear factor-kappa B activity. Am. J. Physiol. Lung Cell. Mol. Physiol. 284 (2003) L197-L204
10. Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533 (2006) 2-14
11. Basu S., and Fenton M.J. Toll-like receptors: function and roles in lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 286 (2004) L887-L892
12. Bensalem N., Ventura A.P., Vallee B., Lipecka J., Tondelier D., Davezac N., et al. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol. Cell. Proteomics 4 (2005) 1591-1601
13. Boncoeur E., Bonvin E., Muselet-Charlier C., Henrion-Caude A., Gruenert D., Clement A., et al. Oxidative stress induces ERK1/2 signaling in cystic fibrosis lung epithelial cells: potentiel mechanism for excessive IL-8 expression. Int. J. Biochem. Cell. Biol. 40 (2008) 432-446
14. Boncoeur, E., Roque, T., Bonvin, E., Saint Criq, V., Bonora, M., Clement, A., et al. (2008). Cystic fibrosis transmembrane conductance regulator controls lung proteasomal degradation and NF-kB activity in conditions of oxidative stress. Am. J. Pathol, 172, in press.
15. Bonora M., Bernaudin J.F., Guernier C., and Brahimi-Horn M.C. Ventilatory responses to hypercapnia and hypoxia in conscious cystic fibrosis knockout mice Cftr. Pediatr Res. 55 (2004) 738-746
16. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23 (2004) 146-158
17. Boucher R.C. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu. Rev. Med. 58 (2007) 157-170
18. Boucher R.C. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol. Med. 13 (2007) 231-240
19. Brown R.K., McBurney A., Lunec J., and Kelly F.J. Oxidative damage to DNA in patients with cystic fibrosis. Free Radic. Biol. Med. 18 (1995) 801-806
20. Bush A., and Davies J. Non! to non-steroidal anti-inflammatory therapy for inflammatory lung disease in cystic fibrosis (at least at the moment). J. Pediatr. 151 (2007) 228-230
21. Cantin A.M., Bilodeau G., Ouellet C., Liao J., and Hanrahan J.W. Oxidant stress suppresses CFTR expression. Am. J. Physiol. Cell. Physiol. 290 (2006) C262-C270
22. Cantin A.M., White T.B., Cross C.E., Forman H.J., Sokol R.J., and Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic. Biol. Med. 42 (2007) 15-31
23. Carrabino S., Carpani D., Livraghi A., Di Cicco M., Costantini D., Copreni E., et al. Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J. Cyst. Fibros (2006)
24. Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A., et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990) 827-834
25. Chmiel J.F., and Davis P.B. State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respir. Res. 4 (2003) 8
26. Chmiel J.F., and Konstan M.W. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir. Med. 4 (2005) 255-273
27. Clarke L.L., Grubb B.R., Yankaskas J.R., Cotton C.U., McKenzie A., and Boucher R.C. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 479-483
28. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., and Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 61 (2006) 895-902
29. Collins F.S., Riordan J.R., and Tsui L.C. The cystic fibrosis gene: isolation and significance. Hosp. Pract. (Off. Ed) 25 (1990) 47-57
30. Corvol H., Fitting C., Chadelat K., Jacquot J., Tabary O., Boule M., et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 284 (2003) L997-L1003
31. Davis P.B., Drumm M., and Konstan M.W. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154 (1996) 1229-1256
32. de Oliveira-Marques V., Cyrne L., Marinho H.S., and Antunes F. A quantitative study of NF-kappaB activation by H2O2: relevance in inflammation and synergy with TNF-alpha. J. Immunol. 178 (2007) 3893-3902
33. Dezateux C., and Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst. Rev. (2000) CD001505
34. DiMango E., Ratner A.J., Bryan R., Tabibi S., and Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J. Clin. Invest. 101 (1998) 2598-2605
35. DiMango E., Zar H.J., Bryan R., and Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J. Clin. Invest. 96 (1995) 2204-2210
36. Dinwiddie R. Anti-inflammatory therapy in cystic fibrosis. J. Cyst. Fibros. 4 Suppl. 2 (2005) 45-48
37. Donaldson S.H., Bennett W.D., Zeman K.L., Knowles M.R., Tarran R., and Boucher R.C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 354 (2006) 241-250
38. Durie P.R., Kent G., Phillips M.J., and Ackerley C.A. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am. J. Pathol. 164 (2004) 1481-1493
39. Egan M.E., Glockner-Pagel J., Ambrose C., Cahill P.A., Pappoe L., Balamuth N., et al. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. 8 (2002) 485-492
40. Eidelman O., Srivastava M., Zhang J., Leighton X., Murtie J., Jozwik C., et al. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway. Mol. Med. 7 (2001) 523-534
41. Eigen H., Rosenstein B.J., FitzSimmons S., and Schidlow D.V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J. Pediatr. 126 (1995) 515-523
42. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C.P., Marks G.B., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 354 (2006) 229-240
43. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
44. Franek W.R., Morrow D.M., Zhu H., Vancurova I., Miskolci V., Darley-Usmar K., et al. NF-kappaB protects lung epithelium against hyperoxia-induced nonapoptotic cell death-oncosis. Free Radic. Biol. Med. 37 (2004) 1670-1679
45. Fu Z., Bettega K., Carroll S., Buchholz K.R., and Machen T.E. Role of Ca2+ in responses of airway epithelia to Pseudomonas aeruginosa, flagellin, ATP, and thapsigargin. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L353-L364
46. Gloire G., Legrand-Poels S., and Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72 (2006) 1493-1505
47. Gomez M.I., and Prince A. Airway epithelial cell signaling in response to bacterial pathogens. Pediatr. Pulmonol. 43 (2008) 11-19
48. Grasemann H., Stehling F., Brunar H., Widmann R., Laliberte T.W., Molina L., et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 131 (2007) 1461-1466
49. Griese M., Ramakers J., Krasselt A., Starosta V., Van Koningsbruggen S., Fischer R., et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am. J. Respir. Crit. Care Med. 169 (2004) 822-828
50. Groux-Degroote S., Krzewinski-Recchi M.A., Cazet A., Vincent A., Lehoux S., Lafitte J.J., et al. IL-6 and IL-8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa. Biochem. J. (2007)
51. Grubb B.R., and Boucher R.C. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol. Rev. 79 (1999) S193-S214
52. Gruenert D.C., Willems M., Cassiman J.J., and Frizzell R.A. Established cell lines used in cystic fibrosis research. J. Cyst. Fibros 3 Suppl 2 (2004) 191-196
53. Guggino W.B., and Stanton B.A. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat. Rev. Mol. Cell Biol. 7 (2006) 426-436
54. Hallows K.R., Fitch A.C., Richardson C.A., Reynolds P.R., Clancy J.P., Dagher P.C., et al. Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. J. Biol. Chem. 281 (2006) 4231-4241
55. Hartl D., Latzin P., Hordijk P., Marcos V., Rudolph C., Woischnik M., et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat. Med. 13 (2007) 1423-1430
56. Hu Y., Baud V., Delhase M., Zhang P., Deerinck T., Ellisman M., et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284 (1999) 316-320
57. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 30 (2001) 1440-1461
58. Hudson V.M. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat. Respir. Med. 3 (2004) 353-363
59. Ianowski J.P., Choi J.Y., Wine J.J., and Hanrahan J.W. Mucus secretion by single tracheal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice. J. Physiol. 580 (2007) 301-314
60. Jacquot J., Puchelle E., Hinnrasky J., Fuchey C., Bettinger C., Spilmont C., et al. Localization of the cystic fibrosis transmembrane conductance regulator in airway secretory glands. Eur. Respir. J. 6 (1993) 169-176
61. Jefferson K.K., Smith Jr. M.F., and Bobak D.A. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J. Immunol. 163 (1999) 5183-5191
62. Joo N.S., Irokawa T., Robbins R.C., and Wine J.J. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. J. Biol. Chem. 281 (2006) 7392-7398
63. Kabe Y., Ando K., Hirao S., Yoshida M., and Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal 7 (2005) 395-403
64. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5 (2004) 388-392
65. Kent G., Iles R., Bear C.E., Huan L.J., Griesenbach U., McKerlie C., et al. Lung disease in mice with cystic fibrosis. J. Clin. Invest. 100 (1997) 3060-3069
66. Kettle A.J., Chan T., Osberg I., Senthilmohan R., Chapman A.L., Mocatta T.J., et al. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 170 (2004) 1317-1323
67. Konstan M.W., Schluchter M.D., Xue W., and Davis P.B. Clinical Use of Ibuprofen is Associated with Slower FEV1 Decline in Children with Cystic Fibrosis. Am. J. Respir. Crit. Care Med. (2007)
68. Kreda S.M., Mall M., Mengos A., Rochelle L., Yankaskas J., Riordan J.R., et al. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol. Biol. Cell 16 (2005) 2154-2167
69. Kube D., Sontich U., Fletcher D., and Davis P.B. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am. J. Physiol. Lung Cell Mol. Physiol. 280 (2001) L493-L502
70. Kwon S.H., Pollard H., and Guggino W.B. Knockdown of NHERF1 enhances degradation of temperature rescued DeltaF508 CFTR from the cell surface of human airway cells. Cell Physiol. Biochem. 20 (2007) 763-772
71. Lagrange-Puget M., Durieu I., Ecochard R., Abbas-Chorfa F., Drai J., Steghens J.P., et al. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. Pediatr. Pulmonol. 38 (2004) 43-49
72. Lands L., and Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst. Rev. (2007) CD001505
73. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir. Res. 7 (2006) 134
74. Li J., Johnson X.D., Iazvovskaia S., Tan A., Lin A., and Hershenson M.B. Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 284 (2003) L307-L315
75. Lilienbaum A., and Israel A. From calcium to NF-kappa B signaling pathways in neurons. Mol. Cell Biol. 23 (2003) 2680-2698
76. Linsdell P., and Hanrahan J.W. Glutathione permeability of CFTR. Am. J. Physiol. 275 (1998) 323-326
77. Liu X., and Zweier J.L. A real-time electrochemical technique for measurement of cellular hydrogen peroxide generation and consumption: evaluation in human polymorphonuclear leukocytes. Free Radic. Biol. Med. 31 (2001) 894-901
78. Lu W., Hisatsune A., Koga T., Kato K., Kuwahara I., Lillehoj E.P., et al. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J. Immunol. 176 (2006) 3890-3894
79. + channels in human normal and cystic fibrosis airway epithelia. Pediatr. Res. 53 (2003) 608-618
80. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10 (2004) 487-493
81. McAuley D.F., and Elborn J.S. Cystic fibrosis: basic science. Paediatr. Respir. Rev. 1 (2000) 93-100
82. McGrath S.A. Induction of p21WAF/CIP1 during hyperoxia. Am. J. Respir. Cell Mol. Biol. 18 (1998) 179-187
83. Medjane S., Raymond B., Wu Y., and Touqui L. Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 289 (2005) L816-L824
84. Meduri G.U., Kanangat S., Stefan J., Tolley E., and Schaberg D. Cytokines IL-1beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria. Am. J. Respir. Crit. Care Med. 160 (1999) 961-967
85. Metrailler-Ruchonnet I., Pagano A., Carnesecchi S., Ody C., Donati Y., and Barazzone Argiroffo C. Bcl-2 protects against hyperoxia-induced apoptosis through inhibition of the mitochondria-dependent pathway. Free Radic. Biol. Med. 42 (2007) 1062-1074
86. Moskwa P., Lorentzen D., Excoffon K.J., Zabner J., McCray Jr. P.B., Nauseef W.M., et al. A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175 (2007) 174-183
87. Moss R.B., Mayer-Hamblett N., Wagener J., Daines C., Hale K., Ahrens R., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr. Pulmonol. 39 (2005) 209-218
88. Mossman B.T., Lounsbury K.M., and Reddy S.P. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am. J. Respir. Cell Mol. Biol. 34 (2006) 666-669
89. Muhlebach M.S., and Noah T.L. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165 (2002) 911-915
90. Muhlebach M.S., Reed W., and Noah T.L. Quantitative cytokine gene expression in CF airway. Pediatr. Pulmonol. 37 (2004) 393-399
91. Muhlebach M.S., Stewart P.W., Leigh M.W., and Noah T.L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am. J. Respir. Crit. Care Med. 160 (1999) 186-191
92. Nichols D., Chmiel J., and Berger M. Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling. Clin. Rev. Allergy Immunol. (2007)
93. Norez C., Noel S., Wilke M., Bijvelds M., Jorna H., Melin P., et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 580 (2006) 2081-2086
94. Ornatowski W., Poschet J.F., Perkett E., Taylor-Cousar J.L., and Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J. Clin. Invest. 117 (2007) 3489-3497
95. Pagano A., and Barazzone-Argiroffo C. Alveolar cell death in hyperoxia-induced lung injury. Ann. NY Acad. Sci. 1010 (2003) 405-416
96. Perez A., Issler A.C., Cotton C.U., Kelley T.J., Verkman A.S., and Davis P.B. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L383-L395
97. Petit-Bertron A.F., Tabary O., Corvol H., Jacquot J., Clement A., Cavaillon J.M., et al. Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine 41 (2008) 54-60
98. Piette J., Piret B., Bonizzi G., Schoonbroodt S., Merville M.P., Legrand-Poels S., et al. Multiple redox regulation in NF-kappaB transcription factor activation. Biol. Chem. 378 (1997) 1237-1245
99. Pilewski J.M., and Frizzell R.A. Role of CFTR in airway disease. Physiol. Rev. 79 (1999) S215-S255
100. Pollard H.B., Ji X.D., Jozwik C., and Jacobowitz D.M. High abundance protein profiling of cystic fibrosis lung epithelial cells. Proteomics 5 (2005) 2210-2226
101. Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem. Biophys. 43 (2005) 167-188
102. Rahman I. Redox signaling in the lungs. Antioxid. Redox Signal. 7 (2005) 1-5
103. Raia V., Maiuri L., Ciacci C., Ricciardelli I., Vacca L., Auricchio S., et al. Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax 60 (2005) 773-780
104. Ratjen F. What's new in CF airway inflammation: an update. Paediatr. Respir. Rev. 7 Suppl 1 (2006) S70-S72
105. Ratjen F., and Doring G. Cystic fibrosis. Lancet 361 (2003) 681-689
106. Ratner A.J., Bryan R., Weber A., Nguyen S., Barnes D., Pitt A., et al. Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J. Biol. Chem. 276 (2001) 19267-19275
107. Reid D.W., Misso N., Aggarwal S., Thompson P.J., and Walters E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 12 (2007) 63-69
108. Reiniger N., Lee M.M., Coleman F.T., Ray C., Golan D.E., and Pier G.B. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect. Immun. 75 (2007) 1598-1608
109. Ribeiro C.M., Paradiso A.M., Carew M.A., Shears S.B., and Boucher R.C. Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia. J. Biol. Chem. 280 (2005) 10202-10209
110. 2+-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J. Biol. Chem. 280 (2005) 17798-17806
111. Roum J.H., Borok Z., McElvaney N.G., Grimes G.J., Bokser A.D., Buhl R., et al. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J. Appl. Physiol. 87 (1999) 438-443
112. Rubin B.K. CFTR is a modulator of airway inflammation. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L381-L382
113. Russell K.J., McRedmond J., Mukherji N., Costello C., Keatings V., Linnane S., et al. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis. Am. J. Respir. Crit. Care Med. 157 (1998) 756-761
114. Saadane A., Masters S., DiDonato J., Li J., and Berger M. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am. J. Respir. Cell Mol. Biol. 36 (2007) 728-736
115. Sadikot R.T., Christman J.W., and Blackwell T.S. Molecular targets for modulating lung inflammation and injury. Curr. Drug Targets 5 (2004) 581-588
116. Sagel S.D., Chmiel J.F., and Konstan M.W. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc. Am. Thorac. Soc. 4 (2007) 406-417
117. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
118. Schiotz P.O., Jorgensen M., Flensborg E.W., Faero O., Husby S., Hoiby N., et al. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr. Scand. 72 (1983) 283-287
119. Scholte B.J., Davidson D.J., Wilke M., and De Jonge H.R. Animal models of cystic fibrosis. J. Cyst. Fibros 3 Suppl 2 (2004) 183-190
120. Schwarzer C., Illek B., Suh J.H., Remington S.J., Fischer H., and Machen T.E. Organelle redox of CF and CFTR-corrected airway epithelia. Free Radic. Biol. Med. 43 (2007) 300-316
121. Schwarzer C., Machen T.E., Illek B., and Fischer H. NADPH oxidase-dependent acid production in airway epithelial cells. J. Biol. Chem. 279 (2004) 36454-36461
122. Sheppard D.N., and Welsh M.J. Structure and function of the CFTR chloride channel. Physiol. Rev. 79 (1999) S23-S45
123. Srivastava M., Eidelman O., Joswik C., Paweletz C., Huang W., Zeitlin P.L., et al. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol. Genet. Metab. (2006)
124. Starosta V., and Griese M. Protein oxidation by chronic pulmonary diseases in children. Pediatr. Pulmonol. 41 (2006) 67-73
125. Strausbaugh S.D., and Davis P.B. Cystic fibrosis: A review of epidemiology and pathobiology. Clin. Chest Med. 28 (2007) 279-288
126. Tabary O., Boncoeur E., de Martin R., Pepperkok R., Clement A., Schultz C., et al. Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells. Cell Signal 18 (2006) 652-660
127. Tabary O., Corvol H., Boncoeur E., Chadelat K., Fitting C., Cavaillon J.M., et al. Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. Am. J. Physiol. Lung Cell Mol. Physiol. 290 (2006) L588-L596
128. Tabary O., Escotte S., Couetil J.P., Hubert D., Dusser D., Puchelle E., et al. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am. J. Pathol. 155 (1999) 473-481
129. Tabary O., Escotte S., Couetil J.P., Hubert D., Dusser D., Puchelle E., et al. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J. Immunol. 164 (2000) 3377-3384
130. Tabary O., Escotte S., Couetil J.P., Hubert D., Dusser D., Puchelle E., et al. Relationship between IkappaBalpha deficiency, NFkappaB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Arch. 443 Suppl 1 (2001) S40-S44
131. Tabary O., Muselet C., Escotte S., Antonicelli F., Hubert D., Dusser D., et al. Interleukin-10 inhibits elevated chemokine interleukin-8 and regulated on activation normal T cell expressed and secreted production in cystic fibrosis bronchial epithelial cells by targeting the I(k)B kinase alpha/beta complex. Am. J. Pathol. 162 (2003) 293-302
132. Tabary O., Zahm J.M., Hinnrasky J., Couetil J.P., Cornillet P., Guenounou M., et al. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am. J. Pathol. 153 (1998) 921-930
133. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., and Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4628-4633
134. Tirouvanziam R., de Bentzmann S., Hubeau C., Hinnrasky J., Jacquot J., Peault B., et al. Inflammation and infection in naive human cystic fibrosis airway grafts [In Process Citation]. Am. J. Respir. Cell Mol. Biol. 23 (2000) 121-127
135. Toledano M.B., and Leonard W.J. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 4328-4332
136. Velsor L.W., Kariya C., Kachadourian R., and Day B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 35 (2006) 579-586
137. Venkatakrishnan A., Stecenko A.A., King G., Blackwell T.R., Brigham K.L., Christman J.W., et al. Exaggerated activation of nuclear factor-kappaB and altered IkappaB- beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 23 (2000) 396-403
138. Verhaeghe C., Remouchamps C., Hennuy B., Vanderplasschen A., Chariot A., Tabruyn S.P., et al. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem. Pharmacol. 73 (2007) 1982-1994
139. - channel function. Am. J. Physiol. Lung Cell Mol. Physiol. 281 (2001) L71-L78
140. Wiszniewski L., Jornot L., Dudez T., Pagano A., Rochat T., Lacroix J.S., et al. Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 34 (2006) 39-48
141. Witko-Sarsat V., Delacourt C., Rabier D., Bardet J., Nguyen A.T., and Descamps-Latscha B. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am. J. Respir. Crit. Care Med. 152 (1995) 1910-1916
142. Witko-Sarsat V., Halbwachs-Mecarelli L., Sermet-Gaudelus I., Bessou G., Lenoir G., Allen R.C., et al. Priming of blood neutrophils in children with cystic fibrosis: correlation between functional and phenotypic expression of opsonin receptors before and after platelet-activating factor priming. J. Infect. Dis. 179 (1999) 151-162
143. Zaman M.M., Gelrud A., Junaidi O., Regan M.M., Warny M., Shea J.C., et al. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin. Diagn. Lab. Immunol. 11 (2004) 819-824